About Dordaviprone Dordaviprone (ONC201) is a first-in-class small molecule imipridone that targets the mitochondrial protease ClpP and dopamine receptor D2 (DRD2), reversing H3 K27me3-loss in H3 K27M ...

Dordaviprone is designed to activate stress responses in cancer cells, pushing them into apoptosis by acting on the mitochondrial protease ClpP and dopamine receptor D2 (DRD2). According to ...

Dordaviprone is designed to activate stress responses in cancer cells, pushing them into apoptosis by acting on the mitochondrial protease ClpP and dopamine receptor D2 (DRD2). According to GlobalData ...

Dopamine receptors are a primary target of the SGAs, and many studies have tested whether variation in the dopamine receptor genes correlate with treatment response and/or side effect profiles.

Coronary artery disease (CAD), or the narrowing of the coronary arteries, is the leading cause of morbidity and mortality throughout the world. Atherosclerosis, or the buildup of plaque in the ...

This indicates that GLP-1 receptor agonists lead to greater reduction in overall body fat than that in muscle mass, resulting in an overall body fat percentage decrease of around 4.5%.

Figure 4. Principle of commonly used chemogenetic receptors. Stimulation of hM3Dq on the cell membrane with CNO initiates downstream signaling cascades that lead to cell depolarization (left). In ...